INTERCEPT Blood System for Red Blood Cells
Pathogen reduction for red blood cell transfusions
Phase 3Late-Stage Clinical Development
Key Facts
Indication
Pathogen reduction for red blood cell transfusions
Phase
Phase 3
Status
Late-Stage Clinical Development
Company
About Cerus
Cerus is a public company focused exclusively on blood safety, aiming to become the preeminent global blood products company. Its flagship INTERCEPT Blood System for platelets and plasma is the only pathogen reduction system with both FDA approval and a CE mark for these components. With a commercial footprint and a late-stage pipeline for red blood cells, Cerus is positioned to address critical safety gaps in the global blood transfusion market.
View full company profile